Healthcare

A new class of cancer detection technologies is poised to revolutionize the field. Through a simple blood draw or breath, urine, saliva, or stool sample, multicancer early detection (MCED) technologies can enable clinicians to rapidly screen for multiple cancer types at once and, in principle, help stop early-stage cancer in its tracks. However, some stakeholders continue to pose questions around the efficacy, value, cost, benefit, and sustainability of these technologies for health systems.

Beginning in mid-2020, Tapestry engaged diverse stakeholders to understand challenges facing MCED adoption and identify approaches for overcoming those challenges. This work laid the foundation for a new organization—the MCED Consortium—to address these issues on a longer-term basis. Tapestry and collaborators co-designed a Consortium Blueprint that outlined the mission, scope, objectives, governance structure, operating model, and multiyear work plans and deliverables for the organization. The Consortium launched as an independent entity in 2021.